ArQule, Inc. has selected Nextrials, Inc.'s clinical trial data collection and management product, Prism, for use in an ongoing Phase I/II trial. ArQule will deploy Prism to replace its paper-based data collection system in a dose-escalation study of the lead product from the company's Cancer Survival Protein (CSP) drug discovery platform.
"As a biotechnology company engaged in innovative small molecule cancer research, ArQule required a more efficient and cost-effective clinical trial data management system to help speed its drug development effort," said James Rogers, co-founder and chief executive officer of Nextrials. "Its latest study was already underway, yet Prism's flexibility enables it to seamlessly integrate into ArQule's existing processes and replace paper-based data collection without study disruption."
Nextrials' Prism is designed specifically for the pharma, biopharma, and medical device markets and combines all of the components of managing clinical trials research into a comprehensive, web-enabled system.